Taranabant

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Template:Short description Template:Cs1 config Template:Drugbox

Taranabant (codenamed MK-0364) is a cannabinoid receptor type 1 (CB1) inverse agonist that was investigated as a potential treatment for obesity due to its anorectic effects.[1][2] It was developed by Merck & Co.

In October 2008, Merck stopped its phase III clinical trials with the drug due to high level of central nervous system side effects, mainly depression and anxiety.[3][4][5][6]

See also

References

<templatestyles src="Reflist/styles.css" />

  1. ↑ Script error: No such module "Citation/CS1".
  2. ↑ Script error: No such module "Citation/CS1".
  3. ↑ Script error: No such module "citation/CS1".
  4. ↑ Script error: No such module "Citation/CS1".
  5. ↑ Script error: No such module "Citation/CS1".
  6. ↑ Script error: No such module "Citation/CS1".

Script error: No such module "Check for unknown parameters".

Template:Anorectics Script error: No such module "Navbox". Template:Cannabinoidergics

Template:Cannabinoid-stub

Retrieved from "http://debianws.lexgopc.com/wiki143/index.php?title=Taranabant&oldid=6592310"